Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World’s First Saliva-Based Exosomal Biomarker “miR-185” as Dual Diagnostic and Therapeutic Target for Oral Cancer Jan 28, 2019
Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit Jan 15, 2019
Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy Jan 3, 2019
Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern Dec 19, 2018
Avalon GloboCare Provides Third Quarter 2018 Business Update; Reports 30% Increase in Revenues Nov 13, 2018
Avalon GloboCare Teams Up with Weill Cornell Medicine to Co-develop Standardization of cGMP-Grade Exosome Isolation and Application of Tissue-Specific Exosomes Oct 9, 2018
Avalon GloboCare Commences Operation of its Core GMP Platform, Epicon Biotech, to Facilitate Clinical Development of Cellular Therapies Sep 20, 2018
Avalon GloboCare Provides Second Quarter 2018 Business Update; Reports 32% Increase in Revenues Aug 15, 2018
